Abstract. Chemoradiotherapy is a useful treatment strategy in patients with locally advanced cancers. In particular, combination of 5-fluorouracil (5-FU) with X-ray irradiation is effective for the treatment of some types of gastrointestinal cancers. We investigated the antitumor effects of combination treatment with X-ray and S-1, a unique formulation of 5-FU, on human cancer xenografts in nude mice and compared the efficacy of this treatment to that of radiotherapy combined with cisplatin, UFT, another oral 5-FU prodrug, and intravenous 5-FU. Tumors implanted into the left hind legs of mice were treated with a dose of 2 or 5 Gy X-ray irradiation on days 1 and 8, and S-1, UFT and 5-FU were administered for 14 days. The efficacy of combined treatment with 8.3 mg/kg S-1 and 2 Gy X-ray irradiation in treating non-small cell lung cancer xenografts (Lu-99 and LC-11) was significantly higher than that of treatment with S-1 alone or 2 Gy X-ray irradiation alone. Although 8.3 mg/kg S-1 and 17.5 mg/kg UFT had equivalent antitumor activity; the antitumor efficacy of combination treatment with S-1 and 2 Gy X-ray irradiation on LC-11 tumors was significantly higher than that of combination treatment with UFT and 2 Gy X-ray irradiation. Combination treatment with S-1 and X-ray irradiation was also more effective against pancreatic tumors than combination treatment with intravenous 5-FU and X-ray irradiation. To elucidate the reason for the increased antitumor efficacy of combination treatment with S-1 and X-ray irradiation, the antitumor effect of gimeracil, one of the components of S-1, was tested in combination with 2 Gy X-ray irradiation. These experiments demonstrated that gimeracil enhanced the efficacy of X-ray irradiation against lung as well as head and neck cancer xenografts in a dose-dependent manner. Furthermore, we observed decreased expression of γ-H2AX protein, a marker of DNA repair, in LC-11 tumors treated with X-ray irradiation and gimeracil compared to that observed in tumors treated with X-ray irradiation alone, suggesting that gimeracil may inhibit rapid repair of X-ray-induced DNA damage in tumors. The present study suggests that chemoradiotherapy using S-1 acts through a novel mechanism and may prove useful in treating patients with locally advanced cancers whose disease progression is difficult to control using chemotherapy alone.

Introduction

Combination of radiotherapy with chemotherapy, also referred to as concurrent chemoradiation, has become a standard strategic practice in the treatment of patients with locally advanced cancers including non-small cell lung, head and neck, oral cavity, and esophageal cancers. Currently, several cytotoxic drugs, including cisplatin (CDDP), 5-fluorouracil (5-FU) and gemcitabine (Gem), are frequently used in combination with fractionated radiation for the treatment of such cancers (1,2).

5-FU, a typical antimetabolite that mainly inhibits DNA synthesis, is widely used to treat patients with breast, head and neck, and gastrointestinal (gastric, colorectal, esophageal, and pancreatic) cancers in combination with other cytotoxic drugs. Recently, it has been used with molecular targeting agents in metastatic or adjuvant settings; therefore, 5-FU-
Based regimens have been employed in radiation therapy (9-13).

Despite the widespread use of 5-FU, chemoradiotherapy with 5-FU has not been used to treat advanced non small-cell lung cancer (NSCLC) because 5-FU exhibits low antitumor efficacy and is not useful as an anticancer drug for treatment of NSCLC.

On the other hand, UFT (tegafur-uracil), an oral 5-FU prodrug, is available to treat NSCLC as adjuvant chemotherapy (14), and in concomitant combination with radiation, UFT has been demonstrated to improve the outcome of patients with locally advanced NSCLC (15).

To further improve the clinical response and reduce 5-FU-induced gastrointestinal (GI) events, we developed S-1, a new oral 5-FU formulation. S-1 is composed of the 5-FU prodrug tegafur, gimeracil (5-chloro-2,4-dihydroxypyridine), which reversibly inhibits dihydropyrimidine dehydrogenase (DPD)-mediated inactivation of 5-FU in the liver and tumors, and potassium oteracil (potassium oxonate), an inhibitor of orotate phosphoribosyltransferase (OPRT) that protects against 5-FU-induced GI damage (16,17). S-1 was found to be clinically effective against NSCLC and pancreatic, gastric, CRC, head and neck, and breast cancers (18-21).

Several reports have suggested that chemoradiotherapy using S-1 in combination with X-ray irradiation is fairly effective against various types of cancer xenografts, and its antitumor effects are mediated by mechanisms including induction of apoptosis, inhibition of survival signals or suppression of radiation-induced hypoxia-inducible factor-1 (HIF-1) activation (22-25). Preliminary clinical studies have demonstrated the potential efficacy of chemoradiotherapy with S-1 and radiation in treating locally advanced head and neck and pancreatic cancers (26,27).

Although chemoradiotherapy with S-1 seems to be a useful treatment option for patients with locally advanced cancers, currently there is no report comparing the efficacy of combination treatment with S-1 and radiation with that of standard chemoradiotherapy.

We compared the antitumor efficacy of chemoradiotherapy with S-1 to that of chemoradiotherapy with 5-FU and/or its prodrug against human cancer xenografts in vivo and found that radiotherapy combined with S-1 was more effective in treating these tumors than conventional chemoradiotherapy and that the increased antitumor efficacy of combination treatment with S-1 and X-ray irradiation is, in a part, mediated by gimeracil, a component of S-1.

The present study reports the enhanced antitumor activity of concurrent chemoradiotherapy with S-1 and X-ray irradiation in comparison to chemoradiotherapy with other anti-cancer drugs and the possible mechanism by which gimeracil may contribute to radiosensitization in human tumor xenografts.

**Materials and methods**

**Chemicals.** 5-Fluorouracil (5-FU) and cisplatin (CDDP) were obtained from Wako Pure Chemicals, Ltd. (Tokyo, Japan). Tegafur (FT), gimeracil (5-chloro-2,4-dihydroxypyridine) and potassium oteracil (potassium oxonate) were products of Taiho Pharmaceutical Co. (Tokyo, Japan). S-1 is a combination of 1 M FT, 0.4 M gimeracil and 1 M potassium oteracil. For immuno-blot analysis of proteins, anti-γ-H2AX monoclonal antibody was purchased from Santa Cruz Biochemicals Inc. (San Diego, CA, USA).

**Animals and tumor xenografts.** Five-week old Balb/c-nu/nu mice were purchased from CLEA Japan Inc. (Tokyo, Japan) and were fed a sterilized pellet diet and autoclaved water *ad libitum*. Mice were housed in laminar air flow units throughout the therapeutic experiments. All animal experiments were performed according to the institutional guidelines.

Human non-small cell lung cancer Lu-99 and LC-11, human head and neck cancer KB/C3, and human pancreatic cancer PAN-4 cells were obtained from the Central Institute for Experimental Animals (Kawasaki, Japan).

**Local tumor irradiation.** Irradiation was performed with a small animal X-ray generator (MBR-1505R2, Hitachi Medical Corp., Tokyo, Japan). Un-anesthetized mice were immobilized on an X-ray-block box, and irradiation was delivered locally to the tumor implanted into the right hind leg while the rest of the body was shielded.

**Antitumor experiments.** Nude mice were divided into groups of six mice each. Lu-99, LC-11, KB/C3 and PAN-4 tumors were xenografted by s.c. implantation of 2-mm³ fragments into the right hind leg of each mouse. After 7 days, S-1 (8.3 mg/kg), UFT (17.5 mg/kg) and gimeracil (2.5-25 mg/kg) were administered orally, 5-FU was intravenously injected for 14 consecutive days, and CDDP (5 and 7.5 mg/kg), was injected on day 1. The tumors implanted into the right hind leg of each mouse were directly X-ray irradiated (2-10 Gy) on days 1 and 8. The tumor volume \[\frac{1}{2} \times (\text{the major axis}) \times (\text{the minor axis})^2\] was measured twice a week throughout the experiments, and relative tumor volume (RTV) was calculated as follows: \[\text{RTV} = (\text{mean tumor volume during therapy})/\text{(mean tumor volume at the beginning of the therapy)}\]. The antitumor effects of S-1, X-ray and a combination of S-1 and X-ray were estimated using the following equation: \[\text{mean inhibition rate of tumor growth (IR, %)} = \left[1 - \frac{\text{mean RTV of drug-treated group}}{\text{mean RTV of control group}}\right] \times 100\].

**Western blot analysis.** Tumors were homogenized in three volumes of 50 mM Tris-HCl (pH 7.6) containing 5 mM MgCl₂, 25 mM KCl and 10 mM 2-mercaptoethanol followed by ultra-sonication for 5 min at 4°C. The homogenates were centrifuged at 105,000 x g for 60 min, and aliquots of the supernatant were subjected to Western blot analysis. The supernatant was heated for 2 min in a boiling water bath and loaded on 12.5% polyacrylamide gels. After electrophoresis, the proteins were electrically transferred to PVDF membranes at 4°C. The proteins were immunologically detected using the Avidin-Biotin-Complex (ABC) method. Anti-human γ-H2AX and anti-human β-actin antibodies were used as primary antibodies, and anti-rabbit IgG was used as a secondary antibody.

**Statistical analysis.** The significance of differences between groups with or without treatment was assessed using Dunnett's test and the Student's t-test.
Results

Antitumor potency of chemoradiotherapy with S-1 against NSCLC xenografts. To determine an optimal dose for combination chemoradiotherapy, we evaluated the antitumor activities of S-1, radiation or a combination of S-1 and radiation on Lu-99 and LC-11 tumors. The minimal toxic dose of S-1 was defined to 8.3 mg/kg in 14 day-treatment periods; this dose resulted in a decrease in body weight of <10% from the initial weight. For radiotherapy, mice were treated with 2, 5 or 10 Gy X-ray irradiation to determine the maximum effect of X-ray alone and define a suitable dose for combination treatment with S-1. As shown in Table I, S-1 treatment resulted in 42-47% and 25-28% inhibition of growth of Lu-99 and LC-11 tumors, respectively. X-ray irradiation showed dose-dependent antitumor activity in the range of 2-5 Gy, but 10 Gy irradiation did not result in a further increase in efficacy. Throughout two antitumor experiments, the combination of S-1 (8.3 mg/kg) with 2 Gy X-ray irradiation resulted in significantly higher antitumor activity than treatment with S-1 alone or 2 Gy X-ray irradiation alone (p<0.05).

Comparison of S-1/X-ray therapy with UFT/X-ray therapy in NSCLC xenografts. Because chemoradiotherapy with UFT and CDDP is used to treat locally advanced NSCLC patients in Japan (15), we compared the antitumor activities of UFT (17.5 mg/kg) and S-1 (8.8 mg/kg), alone and in combination with radiation. Both drugs have similar antitumor efficacy against LC-11 tumors (Fig. 1). However, when combined with 2 Gy irradiation, S-1 significantly augmented (p<0.05) the antitumor activity of radiation therapy against LC-11 tumors, and its potency was similar to that of 5 Gy X-ray irradiation alone; however, combination of UFT with 2 Gy X-ray irradiation did not enhance the antitumor activity of radiation therapy (Fig. 1).

Antitumor activity of chemoradiotherapy with CDDP against NSCLC. Using the same tumor (LC-11) xenograft model, we compared the anticancer effect of combination treatment with X-ray irradiation (2 Gy x 2) and 5 or 7.5 mg/kg CDDP (weekly x 2) to that of chemoradiotherapy with S-1. Treatment with 5 and 7.5 mg/kg CDDP resulted in 40-45% and 55-60% inhibition of tumor growth, respectively, and 2 Gy X-ray irradiation resulted in ~35% inhibition of tumor growth. The antitumor activity of combination treatment with CDDP and X-ray irradiation was not significantly different from the antitumor activities of CDDP alone and/or X-ray irradiation alone (Fig. 2).

Comparison of S-1/X-ray therapy with 5-FU/X-ray therapy in pancreatic cancer xenografts. Chemoradiotherapy with 5-FU is one treatment strategy for patients with locally advanced pancreatic cancer (13). To compare chemoradiotherapy with S-1 to that with 5-FU, the same treatment protocol was performed using oral S-1 (8.3 mg/kg) and i.v. 5-FU (15 mg/kg).

Table I. Antitumor activity and toxicity of S-1, X-ray, and their combination on human non-small cell lung cancer xenografts in mice.

<table>
<thead>
<tr>
<th>Group</th>
<th>Doses</th>
<th>Mean IR (%)</th>
<th>Body weight changes (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>mg/kg</td>
<td>Gy</td>
<td>N</td>
</tr>
<tr>
<td>Lu-99 tumors</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>-</td>
<td>-</td>
<td>6</td>
</tr>
<tr>
<td>S-1</td>
<td>8.3</td>
<td>-</td>
<td>6</td>
</tr>
<tr>
<td>X-ray</td>
<td>-</td>
<td>2</td>
<td>6</td>
</tr>
<tr>
<td>S-1/X-ray</td>
<td>8.3</td>
<td>2</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td>8.3</td>
<td>5</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td>8.3</td>
<td>10</td>
<td>6</td>
</tr>
<tr>
<td>LC-11 tumors</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>-</td>
<td>-</td>
<td>6</td>
</tr>
<tr>
<td>S-1</td>
<td>8.3</td>
<td>-</td>
<td>6</td>
</tr>
<tr>
<td>X-ray</td>
<td>-</td>
<td>2</td>
<td>6</td>
</tr>
<tr>
<td>S-1/X-ray</td>
<td>8.3</td>
<td>2</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td>8.3</td>
<td>5</td>
<td>6</td>
</tr>
</tbody>
</table>

S-1 (8.3 mg/kg) was orally administered once daily for 14 days, and X-ray (2, 5 and 10 Gy) was irradiated on day 1 and 8. Mean IR (inhibition rate of tumor growth, %) was calculated on day 15 and 29. *p<0.05, significantly different from both S-1 alone and 2 Gy X-ray alone by IUT-test.
Both treatments resulted in equal toxicity in PAN-4 pancreatic tumor xenografts. As seen in Fig. 3, combination treatment with S-1 and X-ray irradiation resulted in a significant enhancement of antitumor activity (p<0.01); however, consecutive i.v. administration of 5-FU over a course of 14 days in combination with X-ray irradiation failed to enhance antitumor efficacy, suggesting that in addition to 5-FU, one of the components of S-1 may contribute to radiosensitivity.

**Gimeracil-mediated radiosensitization to X-ray irradiation in vivo.** To investigate whether gimeracil, a component of S-1, contributes to radiosensitivity, LC-11 tumor xenografts were treated with a combination of gimeracil and 2 or 5 Gy X-ray irradiation in vivo. Gimeracil was administered at a dose of 2.5 mg/kg, which is equivalent to the dose contained in 8.3 mg/kg S-1, or a 10-fold higher dose (25 mg/kg), and neither dose resulted in antitumor activity when used alone; however, combination of gimeracil with 2 Gy X-ray irradiation resulted in a dose-dependent enhancement of the efficacy of X-ray irradiation. The antitumor efficacy of combined treatment with gimeracil (25 mg/kg) and 2 Gy X-ray was nearly equivalent to that of 5 Gy X-ray irradiation as shown in Fig. 4. Similarly, we evaluated the sensitizing effect of 50 mg/kg of gimeracil in combination with 2 or 5 Gy X-ray irradiation against KB/3 head and neck cancer xenografts in mice (Fig. 5). Similar to the results in the LC-11 tumor xenograft model, gimeracil significantly (p<0.01) potentiated the antitumor effect of 2 Gy X-ray irradiation against KB/3 tumor xenografts.

**Effect of gimeracil on expression of DNA repair protein.** The effect of gimeracil administration on repair of radiation-induced DNA damage was determined in LC-11 tumor xenografts. Tumor-bearing mice were X-ray irradiated (2 Gy) and administered 25 mg/kg gimeracil. Oral gimeracil treatment was continued for two days. On days 1 and 3, tumors were resected, and the expression of $\gamma$-H2AX protein in tumors was assessed. As shown in Fig. 6, the expression of $\gamma$-H2AX in LC-11 tumors increased 24 h after irradiation and then decreased by day 3; however, accumulation of $\gamma$-H2AX
proteins was markedly decreased in tumors treated with gimeracil, suggesting that gimeracil may inhibit the rapid repair of X-ray-induced DNA damage in tumors.

Discussion

Chemoradiotherapy with cytotoxic drugs is the most widely available therapeutic method to treat locally advanced cancers and is used to treat patients with head and neck, lung and GI cancers. In chemoradiotherapy, cytotoxic drugs including 5-FU and CDDP are concomitantly combined with fractionated radiotherapy; however, 5-FU has not been used to treat NSCLC patients because it has low clinical activity against this type of cancer.

The present study was initiated to clarify whether S-1, a unique oral 5-FU formulation, enhances the antitumor efficacy of X-ray irradiation against human NSCLC and pancreatic cancers, which are difficult to treat. Combination of the minimum toxic dose of S-1 with two weekly 2 Gy X-ray irradiation treatments resulted in significantly (p<0.05) higher antitumor activity against NSCLC xenografts (Lu-99 and LC-11) than either treatment alone (Table I). Because UFT (a 5-FU prodrug consisting of tegafur and uracil) is used to treat patients with locally advanced NSCLC in combination with radiation in Japan (15), we compared the antitumor potencies of S-1 and UFT combined with X-ray irradiation against LC-11 tumor xenografts in vivo.

Treatment with either 8.3 mg/kg S-1 or 17.5 mg/kg UFT resulted in similar antitumor activities; however, S-1 treatment resulted in higher antitumor activity than UFT treatment in combination with 2 Gy X-ray irradiation. These results suggest that a component of S-1 different from UFT contributes to sensitization to radiation.

Because CDDP-based chemotherapy is frequently employed in chemoradiotherapy to treat NSCLC patients, the combined activity of CDDP (5 and 7.5 mg/kg) with 2 Gy X-ray irradiation was assessed. Combined CDDP and X-ray irradiation treatment resulted in little enhancement of tumor-inhibitory activity against LC-11 tumor xenografts. Unlike the radiation dosing schedules used in clinical practice, weekly and twice weekly schedules of X-ray irradiation were employed in this study to avoid damage in tumor-bearing mice due to frequent X-ray treatment; therefore, it would likely be difficult to observe an obvious sensitizing effect of CDDP to X-ray irradiation.
We further compared the efficacy of S-1/X-ray therapy to that of 5-FU/X-ray therapy against PAN-4 pancreatic tumors by using the common minimum toxic doses of both drugs, and found that the combination of S-1 (8.3 mg/kg) with X-ray irradiation (2 Gy) resulted in higher efficacy than the combination of i.v. 5-FU (15 mg/kg) with X-ray irradiation (2 Gy), suggesting that a component of S-1 contributed to radiosensitization (Fig. 3).

Gimeracil, a component of S-1, is an inhibitor of DPD and strongly inhibits the degradation of 5-FU as well as the catabolism of the natural pyrimidine uracil in the liver and tumors; therefore, elevated concentrations of natural pyrimidine may affect the antitumor activity of radiation. Although large amounts of uracil (100-200 mg/kg) were administered consecutively in combination with 2 Gy X-ray irradiation, no difference was detected in the anti-tumor activity of radiation with or without uracil (data not shown). As shown in Figs. 4 and 5, treatment with gimeracil, which showed no anticancer activity on its own, enhanced the antitumor activity of X-ray irradiation against two tumor xenograft model (LC-11 and PAN-4) in a dose-dependent manner, suggesting that in addition to the cytotoxic function of 5-FU or CDDP, gimeracil may contribute to sensitization to radiotherapy. The detailed functional mechanism by which gimeracil enhances the antitumor effects of X-ray irradiation remains unclear, but our preliminary results as shown in Fig. 6 suggest that gimeracil may directly or indirectly inhibit the repair of radiation-induced DNA damage in tumors. Further in vitro and in vivo studies are necessary to investigate the inhibition of DNA repair by gimeracil during radiotherapy.

Although the effects of various inhibitors of DNA repair, such as poly (ADP-ribose) polymerase and related enzymes have been studied in vitro (28-30), there are currently no clinically available radiosensitizing drugs. Accordingly, gimeracil, which is in clinical use for the treatment of cancer as a component of S-1, may be considered a valuable therapeutic agent due to its ability to sensitize tumors to radiation. Throughout the in vivo experiments described in this study, the advantages of chemoradiotherapy with S-1 over chemoradiotherapy with 5-FU and its prodrugs should be noted. Treatment with gimeracil results in inhibition of repair of radiation-induced DNA damage in addition to direct enhancement by anticancer drugs of the initial radiation damage by their incorporation into DNA, inhibition by cytotoxic drugs of cellular repair, accumulation of tumor cells in a radiosensitive phase or elimination of radioresistant phase cells due to treatment with anticancer drugs, elimination of...
hypoxic cells after drug treatment, and inhibition by anti-cancer drugs of the accelerated repopulation of tumor cells (31).

References